GILD
Gilead Sciences Inc
NASDAQ: GILD · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$125.59
-0.22% today
Updated 2026-06-12
Market cap
$158.39B
P/E ratio
17.36
P/S ratio
5.33x
EPS (TTM)
$7.35
Dividend yield
2.43%
52W range
$102 – $156
Volume
6.4M
WallStSmart proprietary scores
68
out of 100
Grade: B
Buy
Investment rating
6.0
Growth
B6.5
Quality
B9.5
Profitability
A+7.3
Valuation
B+7/9
Piotroski F-Score
Strong
2.0
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$156.93
+24.95%
12-Month target
$138.43
+10.22%
Intrinsic (DCF)
$221.22
Margin of safety
+41.61%
6 Strong Buy18 Buy7 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Piotroski 7/9 — strong financial health
+ Profit margin 31.00% — above average
+ ROE 39.19% — strong efficiency
+ Free cash flow $2.43B — positive
+ 41.61% below intrinsic value
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $27.28B | $27.12B | $28.75B | $29.44B | $29.74B | $31.1B |
| Net income | $4.59B | $5.67B | $480.00M | $8.51B | $2.02B | — |
| EPS | — | — | — | — | $7.35 | $8.50 |
| Free cash flow | $8.34B | $7.42B | $10.30B | $9.46B | $2.43B | — |
| Profit margin | 16.83% | 20.89% | 1.67% | 28.90% | 31.00% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-10 | O'DAY, DANIEL PATRICK | Sale | 8,779 | — |
| 2026-06-10 | O'DAY, DANIEL PATRICK | Buy | 8,779 | — |
| 2026-06-10 | O'DAY, DANIEL PATRICK | Sale | 4,213 | $121.48 |
Peer comparison
Smart narrative
Gilead Sciences Inc trades at $125.59. representing a P/E of 17.36x trailing earnings. Our Smart Value Score of 68/100 indicates the stock is good. The company scores 7/9 on the Piotroski F-Score. With an Altman Z-Score of 1.97, it sits in the grey zone. TTM revenue stands at $29.74B. with profit margins at 31.00%. Our DCF model estimates intrinsic value at $221.22.
Frequently asked questions
What is Gilead Sciences Inc's stock price?
Gilead Sciences Inc (GILD) trades at $125.59, on a P/E of 17.4x and a P/S of 5.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Gilead Sciences Inc overvalued?
Gilead Sciences Inc carries a Smart Value Score of 68/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $221.22 versus the $125.59 price, a 41.6% margin of safety on a cash flow basis.
What is the price target of Gilead Sciences Inc (GILD)?
The 12-month analyst consensus target is $156.93, about 25.0% above the current $125.59. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of GILD by 2030?
Our research-backed model puts the 2030 base case at $105.40, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Gilead Sciences Inc (GILD)?
Our DCF model estimates intrinsic value at $221.22, a +41.6% margin of safety versus today's $125.59. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Gilead Sciences Inc's revenue?
Gilead Sciences Inc's trailing twelve-month revenue is $29.74B, and our model projects it reaching about $41.22B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Gilead Sciences Inc's Altman Z-Score is 1.97, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.33x
ROE39.19%
Beta0.33
50D MA$134.71
200D MA$128.75
Shares out1.24B
Float1.24B
Short ratio—
Avg volume6.4M
Performance
1 week+0.00%
1 month-0.32%
3 months-11.05%
YTD+5.23%
1 year—
3 years—
5 years—